Creative Medical Technology Holdings, Inc. (CELZ) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CELZ SEC filings page.
Creative Medical Technology Holdings, Inc. (CELZ) reported $6K in revenue for fiscal year 2025, down 45.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Creative Medical remains development-stage: tiny revenue is outweighed by research spending and recurring operating cash use, financed largely through new capital.
Cash needs are persistent rather than episodic: operating cash flow was negative at$8.0M in FY2023,$5.3M in FY2024, and$5.9M in FY2025, while revenue stayed below$11K . That combination indicates the reported business is still funding development activity rather than converting sales into self-generated cash.
Research intensity dominates the economics: FY2025 R&D spending reached
The balance sheet is lightly liability-funded: FY2025 liabilities were
Financial Health Signals
Creative Medical Technology Holdings, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Creative Medical Technology Holdings, Inc. scores -0.75, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($6.4M) relative to total liabilities ($285K). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Creative Medical Technology Holdings, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Creative Medical Technology Holdings, Inc. reported a net loss of $6.0M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Creative Medical Technology Holdings, Inc. generated $0 in revenue in Q2 2026.
Creative Medical Technology Holdings, Inc. reported -$1.5M in net income in Q2 2026. This represents a decrease of 22.6% from the same quarter a year earlier. Against the prior quarter it is down 7.6%.
Creative Medical Technology Holdings, Inc. earned -$0.41 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 7.9%.
Not reported for Q2 2026.
Cash & Balance Sheet
Creative Medical Technology Holdings, Inc. held $8.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Creative Medical Technology Holdings, Inc.'s ROE was -17.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.5 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Creative Medical Technology Holdings, Inc. invested $459K in research and development in Q2 2026. This represents a decrease of 8.4% from the same quarter a year earlier. Against the prior quarter it is down 15.2%.
Creative Medical Technology Holdings, Inc. repurchased no shares in Q2 2026.
Not reported for Q2 2026.
CELZ Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0-100.0% | N/A | $0 | $0-100.0% | $3K | N/A | $0-100.0% |
| Cost of Revenue | $0 | $0-100.0% | N/A | $0 | $0-100.0% | $1K | N/A | $0-100.0% |
| Gross Profit | $0 | $0-100.0% | N/A | $0 | $0-100.0% | $2K | N/A | $0-100.0% |
| R&D Expenses | $459K-8.4% | $542K-27.1% | N/A | $465K-20.0% | $501K-45.8% | $743K+76.0% | N/A | $582K-41.4% |
| SG&A Expenses | $1.1M+47.6% | $889K0.0% | N/A | $777K+55.8% | $732K+8.2% | $888K+32.3% | N/A | $499K-6.1% |
| Operating Income | -$1.6M-23.6% | -$1.5M+12.1% | N/A | -$1.3M-14.7% | -$1.3M+22.3% | -$1.7M-47.8% | N/A | -$1.1M+28.1% |
| EBITDA | N/A | N/A | N/A | N/A | N/A | -$1.6M-49.9% | N/A | -$1.1M |
| Income Tax | $0 | $0 | N/A | $0 | $0 | $0 | N/A | $0 |
| Net Income | -$1.5M-22.6% | -$1.4M+14.2% | N/A | -$1.2M-18.8% | -$1.2M+20.8% | -$1.6M-57.3% | N/A | -$1.0M+28.5% |
| EPS (Diluted) | -$0.41 | -$0.38 | -$0.80+28.6% | -$0.48 | -$0.48 | -$0.83 | -$1.12 | -$0.75 |
| Diluted Shares (Avg) | 4M | 4M | N/A | 3M | 3M | 2M | N/A | 1M |
Not reported in any period shown, so not listed: Interest Expense, EPS (Basic).
CELZ Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.4M+32.0% | $6.4M-22.8% | $7.8M+17.1% | $5.9M-15.0% | $7.1M-11.1% | $8.3M-13.2% | $6.7M-37.8% | $6.9M-45.0% |
| Current Assets | $9.0M+36.0% | $6.1M-22.8% | $7.4M+20.6% | $5.4M-14.5% | $6.6M-12.8% | $7.8M-14.8% | $6.1M-40.3% | $6.3M-47.4% |
| Cash & Equivalents | $8.7M+33.0% | $5.7M-25.7% | $7.2M+21.3% | $5.4M-14.1% | $6.6M-12.3% | $7.7M-14.5% | $5.9M+71.3% | $6.3M+38.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $125K+12475.5% | $125K+12475.5% | $0-100.0% | $994-70.7% | $994-70.7% | $994-84.9% | $2K-66.7% | $3K-56.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $699K+151.6% | $308K+7.4% | $285K-13.1% | $261K-21.0% | $278K-26.2% | $286K-26.7% | $328K-11.8% | $331K-21.4% |
| Current Liabilities | $699K+151.6% | $308K+7.4% | $285K-13.1% | $261K-21.0% | $278K-26.2% | $286K-26.7% | $328K-11.8% | $331K-21.4% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Equity | $8.7M+26.8% | $6.1M-24.2% | $7.5M+18.5% | $5.6M-14.7% | $6.8M-10.3% | $8.1M-12.7% | $6.3M-38.7% | $6.6M-45.8% |
| Retained Earnings | -$73.5M-9.0% | -$72.0M-8.7% | -$70.6M-9.3% | -$68.7M-9.5% | -$67.5M-9.3% | -$66.2M-10.1% | -$64.6M-9.3% | -$62.7M-9.3% |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
CELZ Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.5M-27.1% | -$1.3M+16.9% | -$1.9M+0.6% | -$1.2M-18.6% | -$1.2M+21.1% | -$1.6M-77.5% | -$1.9M-2.9% | -$986K+24.4% |
| Depreciation & Amortization | N/A | N/A | N/A | N/A | N/A | $46K0.0% | $10K | $0 |
| Stock-Based Compensation | N/A | $0-100.0% | N/A | N/A | N/A | $3K-62.0% | N/A | $9K0.0% |
| Investing Cash Flow | $0 | -$175K | -$51K | $0+100.0% | $0 | $0-100.0% | $0-100.0% | -$200K-109.9% |
| Financing Cash Flow | $4.5M | $13K-99.6% | $3.8M+134.5% | $0+100.0% | $0+100.0% | $3.4M+4150.9% | $1.6M+2158.2% | -$25K+86.7% |
| Share Buybacks | $0 | $0-100.0% | $0 | $0-100.0% | $0-100.0% | $10K-87.9% | $0-100.0% | $25K-86.7% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.
CELZ Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | 60.0% | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | -55349.3% | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -54603.2% | N/A | N/A |
| Return on Equity | -17.5%+0.6pp | -23.0%-2.7pp | N/A | -22.1%-6.2pp | -18.1%+2.4pp | -20.3%-9.0pp | N/A | -15.9%-3.8pp |
| Return on Assets | -16.1%+1.2pp | -21.8%-2.2pp | N/A | -21.1%-6.0pp | -17.4%+2.1pp | -19.6%-8.8pp | N/A | -15.1%-3.5pp |
| Current Ratio | 12.91-11.0x | 19.69-7.7x | 25.97+7.2x | 20.71+1.6x | 23.89+3.7x | 27.39+3.8x | 18.73-8.9x | 19.13-9.5x |
| Debt-to-Equity | 0.080.0x | 0.050.0x | 0.040.0x | 0.050.0x | 0.040.0x | 0.040.0x | 0.050.0x | 0.050.0x |
| Asset Turnover | 0.000.0x | 0.000.0x | N/A | 0.000.0x | 0.000.0x | 0.000.0x | N/A | 0.000.0x |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Creative Medical Technology Holdings, Inc. CELZ | FY2025 | $6K | -$6.0M | N/A | $6.4M | — |
| Ernexa Therapeutics Inc. ERNA | FY2025 | N/A | -$14.1M | N/A | $2.8M | — |
| IN8bio, Inc. INAB | FY2025 | N/A | -$19.4M | N/A | $13.2M | — |
| TransCode Therapeutics, Inc. RNAZ | FY2025 | N/A | -$34.7M | N/A | $31.5M | — |
| Aprea Therapeutics, Inc. APRE | FY2025 | N/A | -$12.6M | N/A | $7.6M | — |
| NLS Pharmaceutics Ltd. NLSP | FY2025 | N/A | -$8.3M | N/A | $4.0M | — |
Where Creative Medical Technology Holdings, Inc. Ranks
Frequently Asked Questions
What is Creative Medical Technology Holdings, Inc.'s annual revenue?
Creative Medical Technology Holdings, Inc. (CELZ) reported $6K in total revenue for fiscal year 2025. This represents a -45.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Creative Medical Technology Holdings, Inc.'s revenue growing?
Creative Medical Technology Holdings, Inc. (CELZ) revenue declined by 45.5% year-over-year, from $11K to $6K in fiscal year 2025.
Is Creative Medical Technology Holdings, Inc. profitable?
No, Creative Medical Technology Holdings, Inc. (CELZ) reported a net income of -$6.0M in fiscal year 2025.
What is Creative Medical Technology Holdings, Inc.'s gross margin?
Creative Medical Technology Holdings, Inc. (CELZ) had a gross margin of 63.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Creative Medical Technology Holdings, Inc.'s return on equity (ROE)?
Creative Medical Technology Holdings, Inc. (CELZ) has a return on equity of -79.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Creative Medical Technology Holdings, Inc.'s operating cash flow?
Creative Medical Technology Holdings, Inc. (CELZ) recorded an outflow of $5.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Creative Medical Technology Holdings, Inc.'s total assets?
Creative Medical Technology Holdings, Inc. (CELZ) had $7.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Creative Medical Technology Holdings, Inc. spend on research and development?
Creative Medical Technology Holdings, Inc. (CELZ) invested $2.3M in research and development during fiscal year 2025.
What is Creative Medical Technology Holdings, Inc.'s current ratio?
Creative Medical Technology Holdings, Inc. (CELZ) had a current ratio of 25.97 as of fiscal year 2025, which is generally considered healthy.
What is Creative Medical Technology Holdings, Inc.'s debt-to-equity ratio?
Creative Medical Technology Holdings, Inc. (CELZ) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Creative Medical Technology Holdings, Inc.'s return on assets (ROA)?
Creative Medical Technology Holdings, Inc. (CELZ) had a return on assets of -76.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Creative Medical Technology Holdings, Inc.'s P/E ratio?
Creative Medical Technology Holdings, Inc. (CELZ) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $6.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Creative Medical Technology Holdings, Inc.'s price-to-sales ratio?
Creative Medical Technology Holdings, Inc. (CELZ) has no price-to-sales ratio at the moment: outside the range published as a multiple (on $6K revenue, FY2025). The market capitalization is $6.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Creative Medical Technology Holdings, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Creative Medical Technology Holdings, Inc. (CELZ) held $7.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.9M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Creative Medical Technology Holdings, Inc.'s Altman Z-Score?
Creative Medical Technology Holdings, Inc. (CELZ) has an Altman Z-Score of -0.75, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Creative Medical Technology Holdings, Inc.'s Piotroski F-Score?
Creative Medical Technology Holdings, Inc. (CELZ) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Creative Medical Technology Holdings, Inc.'s earnings high quality?
Creative Medical Technology Holdings, Inc. (CELZ) reported a net loss of $6.0M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.